The intestinal microbiota and host immune interactions in the critically ill

Trends in Microbiology

Volumn 21, Issue 5, 2013, Pages 221-229

  Schuijt, Tim J ^a   van der Poll, Tom ^a   de Vos, Willem M ^b,c   Wiersinga, W Joost ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Critically ill; Intestinal flora; Microbiota; Priming; Sepsis; Translocation

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOCIN; HYPERTENSIVE AGENT; IMMUNOGLOBULIN A ANTIBODY; NARCOTIC ANALGESIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; SECRETORY IMMUNOGLOBULIN; SHORT CHAIN FATTY ACID; TOLL LIKE RECEPTOR;

ACTINOBACTERIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BACTEROIDES; CLOSTRIDIUM DIFFICILE INFECTION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; FECAL MICROBIOTA TRANSPLANTATION; FIRMICUTES; HOMEOSTASIS; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; INTENSIVE CARE; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE MUCOSA; LACTOBACILLUS RHAMNOSUS; MICROBIAL COMMUNITY; MUCOSAL IMMUNITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSFUSION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIA; CRITICAL ILLNESS; DRUG THERAPY; HUMANS; IMMUNITY; INTESTINES; METAGENOME;

EID: 84877148030     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2013.02.001     Document Type: Review

References (80)

1. Clark J.A., Coopersmith C.M. Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness. Shock 2007, 28:384-393.
2. Arumugam M., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
3. Eckburg P.B., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
4. Schuijt T.J., et al. Gut microbiome and host defense interactions during critical illness. Annual Update in Intensive Care and Emergency Medicine 2012 2012, 29-40. Springer. J.L. Vincent (Ed.).
5. de Vos W.M., de Vos E.A. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr. Rev. 2012, 70:S45-S56.
6. Zoetendal E.G., et al. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008, 57:1605-1615.
7. Zoetendal E.G., et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. ISME J. 2012, 6:1415-1426.
8. Jeffery I.B., et al. Categorization of the gut microbiota: enterotypes or gradients?. Nat. Rev. Microbiol. 2012, 10:591-592.
9. Gill S.R., et al. Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355-1359.
10. Rakoff-Nahoum S., et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
11. Manges A.R., et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J. Infect. Dis. 2010, 202:1877-1884.
12. Carvalho F.A., et al. Toll-like receptor-gut microbiota interactions: perturb at your own risk! Annu. Rev. Physiol. 2012, 74:177-198.
13. Arthur J.C., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
14. Honda K., Littman D.R. The microbiome in infectious disease and inflammation. Annu. Rev. Immunol. 2012, 30:759-795.
15. Tlaskalova-Hogenova H., et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell. Mol. Immunol. 2011, 8:110-120.
16. Gillor O., et al. The dual role of bacteriocins as anti- and probiotics. Appl. Microbiol. Biotechnol. 2008, 81:591-606.
17. Sturme M.H., et al. Cell to cell communication by autoinducing peptides in Gram-positive bacteria. Antonie van Leeuwenhoek 2002, 81:233-243.
18. Kane M., et al. Successful transmission of a retrovirus depends on the commensal microbiota. Science 2011, 334:245-249.
19. Kuss S.K., et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 2011, 334:249-252.
20. Schaible U.E., Kaufmann S.H. A nutritive view on the host-pathogen interplay. Trends Microbiol. 2005, 13:373-380.
21. Kau A.L., et al. Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
22. Devkota S., et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012, 487:104-108.
23. Belzer C., de Vos W.M. Microbes inside - from diversity to function: the case of Akkermansia. ISME J. 2012, 6:1449-1458.
24. Vinolo M.A., et al. Regulation of inflammation by short chain fatty acids. Nutrients 2011, 3:858-876.
25. Hamer H.M., et al. Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther. 2008, 27:104-119.
26. Wells J.M., et al. Epithelial crosstalk at the microbiota-mucosal interface. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4607-4614.
27. Abreu M.T., et al. TLR signaling at the intestinal epithelial interface. J. Endotoxin Res. 2003, 9:322-330.
28. Akira S., et al. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
29. Lala S., et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 2003, 125:47-57.
30. Shibolet O., Podolsky D.K. TLRs in the gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G1469-G1473.
31. Abreu M.T. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat. Rev. Immunol. 2010, 10:131-144.
32. Lee J., et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat. Cell Biol. 2006, 8:1327-1336.
33. Vijay-Kumar M., et al. Deletion of TLR5 results in spontaneous colitis in mice. J. Clin. Invest. 2007, 117:3909-3921.
34. Vijay-Kumar M., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
35. Caricilli A.M., et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol. 2011, 9:e1001212.
36. Ubeda C., et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J. Exp. Med. 2012, 209:1445-1456.
37. McGuckin M.A., et al. Mucin dynamics and enteric pathogens. Nat. Rev. Microbiol. 2011, 9:265-278.
38. Strugnell R.A., Wijburg O.L. The role of secretory antibodies in infection immunity. Nat. Rev. Microbiol. 2010, 8:656-667.
39. Shulzhenko N., et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat. Med. 2011, 17:1585-1593.
40. Clarke T.B., et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med. 2010, 16:228-231.
41. Ichinohe T., et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:5354-5359.
42. Abt M.C., et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 2012, 37:158-170.
43. Ganal S.C., et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 2012, 37:171-186.
44. Meijer K., et al. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health?. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:715-721.
45. de Jong H.K., et al. The systemic pro-inflammatory response in sepsis. J. Innate Immun. 2010, 2:422-430.
46. Taylor D.E. Revving the motor of multiple organ dysfunction syndrome. Gut dysfunction in ARDS and multiorgan failure. Respir. Care Clin. N. Am. 1998, 4:611-631. vii-viii.
47. Alverdy J.C., Chang E.B. The re-emerging role of the intestinal microflora in critical illness and inflammation: why the gut hypothesis of sepsis syndrome will not go away. J. Leukoc. Biol. 2008, 83:461-466.
48. Shimizu K., et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig. Dis. Sci. 2011, 56:1171-1177.
49. Shimizu K., et al. Altered gut flora and environment in patients with severe SIRS. J. Trauma 2006, 60:126-133.
50. Shimizu K., et al. Probiotic/synbiotic therapy for treating critically ill patients from a gut microbiota perspective. Dig. Dis. Sci. 2013, 58:23-32.
51. Shimizu K., et al. Patterns of Gram-stained fecal flora as a quick diagnostic marker in patients with severe SIRS. Dig. Dis. Sci. 2011, 56:1782-1788.
52. Spitz J., et al. Enteropathogenic Escherichia coli adherence to intestinal epithelial monolayers diminishes barrier function. Am. J. Physiol. 1995, 268:G374-G379.
53. Hotchkiss R.S., et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 1999, 27:1230-1251.
54. Coopersmith C.M., et al. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. JAMA 2002, 287:1716-1721.
55. Alverdy J.C. During critical illness the gut does not pass the acid test. Crit. Care 2012, 16:150.
56. Morowitz M.J., et al. Contributions of intestinal bacteria to nutrition and metabolism in the critically ill. Surg. Clin. North Am. 2011, 91:771-785. viii.
57. Hill D.A., et al. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol. 2010, 3:148-158.
58. Sommer M.O., Dantas G. Antibiotics and the resistant microbiome. Curr. Opin. Microbiol. 2011, 14:556-563.
59. Ambrose N.S., et al. The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile. J. Antimicrob. Chemother. 1985, 15:319-326.
60. Vincent J.L., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
61. Brandl K., et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 2008, 455:804-807.
62. Willing B.P., et al. Shifting the balance: antibiotic effects on host-microbiota mutualism. Nat. Rev. Microbiol. 2011, 9:233-243.
63. Ubeda C., et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J. Clin. Invest. 2010, 120:4332-4341.
64. de Jonge E., et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003, 362:1011-1016.
65. de Smet A.M., Bonten M.J. Selective decontamination of the digestive tract. Curr. Opin. Infect. Dis. 2008, 21:179-183.
66. de Smet A.M., et al. For whom should we use selective decontamination of the digestive tract?. Curr. Opin. Infect. Dis. 2012, 25:211-217.
67. Vincent J.L., Jacobs F. Effect of selective decontamination on antibiotic resistance. Lancet Infect. Dis. 2011, 11:337-338.
68. Ubeda C., Pamer E.G. Antibiotics, microbiota, and immune defense. Trends Immunol. 2012, 33:459-466.
69. Boomer J.S., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
70. Philpott D.J., Girardin S.E. Gut microbes extend reach to systemic innate immunity. Nat. Med. 2010, 16:160-161.
71. Khoruts A., Sadowsky M.J. Therapeutic transplantation of the distal gut microbiota. Mucosal Immunol. 2011, 4:4-7.
72. Vrieze A., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916.
73. van Nood E., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 2013, 368:407-415.
74. Morrow L.E., et al. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am. J. Respir. Crit. Care Med. 2010, 182:1058-1064.
75. Morrow L.E. Probiotics in the intensive care unit. Curr. Opin. Crit. Care 2009, 15:144-148.
76. Petrof E.O., et al. Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit. Care Med. 2012, 40:3290-3302.
77. Gu W.J., et al. Lack of efficacy of probiotics in preventing ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. Chest 2012, 142:859-868.
78. Crooks N.H., et al. Clinical review: probiotics in critical care. Crit. Care 2012, 16:237.
79. Quigley E.M. Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. Nutr. Clin. Pract. 2012, 27:195-200.
80. Yatsunenko T., et al. Human gut microbiome viewed across age and geography. Nature 2012, 486:222-227.